This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Diffusion Pharmaceuticals Future Growth
Future criteria checks 0/6
Key information
21.4%
Earnings growth rate
41.9%
EPS growth rate
| Biotechs earnings growth | 31.3% |
| Revenue growth rate | 66.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 3 | -15 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -18 | N/A | N/A | 2 |
| 12/31/2023 | N/A | -17 | N/A | N/A | 2 |
| 12/31/2022 | N/A | -16 | N/A | N/A | 2 |
| 9/30/2022 | N/A | -15 | -15 | -15 | N/A |
| 6/30/2022 | N/A | -24 | -15 | -15 | N/A |
| 3/31/2022 | N/A | -24 | -14 | -14 | N/A |
| 12/31/2021 | N/A | -24 | -15 | -15 | N/A |
| 9/30/2021 | N/A | -25 | -15 | -15 | N/A |
| 6/30/2021 | N/A | -17 | -15 | -15 | N/A |
| 3/31/2021 | N/A | -18 | -15 | -15 | N/A |
| 12/31/2020 | N/A | -16 | -14 | -14 | N/A |
| 9/30/2020 | N/A | -16 | -13 | -13 | N/A |
| 6/30/2020 | N/A | -14 | -11 | -11 | N/A |
| 3/31/2020 | N/A | -12 | -11 | -11 | N/A |
| 12/31/2019 | N/A | -12 | -10 | -10 | N/A |
| 9/30/2019 | N/A | -14 | -10 | -10 | N/A |
| 6/30/2019 | N/A | -18 | -10 | -10 | N/A |
| 3/31/2019 | N/A | -18 | -10 | -10 | N/A |
| 12/31/2018 | N/A | -27 | -11 | -11 | N/A |
| 9/30/2018 | N/A | -20 | -10 | -10 | N/A |
| 6/30/2018 | N/A | -10 | -12 | -12 | N/A |
| 3/31/2018 | N/A | 4 | -13 | -12 | N/A |
| 12/31/2017 | N/A | -3 | -13 | -12 | N/A |
| 9/30/2017 | N/A | -7 | -12 | -11 | N/A |
| 6/30/2017 | N/A | -15 | -10 | -9 | N/A |
| 3/31/2017 | N/A | -30 | -10 | -10 | N/A |
| 12/31/2016 | N/A | -18 | -11 | -11 | N/A |
| 9/30/2016 | N/A | -18 | -12 | -12 | N/A |
| 6/30/2016 | N/A | -14 | N/A | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DP81 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DP81 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DP81 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DP81 is forecast to have no revenue next year.
High Growth Revenue: DP81 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DP81's Return on Equity is forecast to be high in 3 years time